A groundbreaking study challenges the effectiveness of a brain device for ADHD, despite its FDA approval. But is it a case of misplaced trust or a necessary step towards better treatment?
The Controversial Device:
A recent multicentre clinical trial, involving the University of Southampton, has revealed a startling truth about a device previously approved by the FDA to treat ADHD. This device, utilizing trigeminal nerve stimulation (TNS), was initially cleared based on a small-scale study.
But here's where it gets controversial: the new, larger trial involving 150 children and adolescents suggests that the device might not be as effective as once thought. The study, published in Nature Medicine, raises questions about the original evidence that led to FDA approval. Interestingly, UK guidelines currently do not recommend TNS for ADHD treatment.
The Quest for Alternative Treatments:
ADHD, affecting 5-8% of school-aged children globally, is characterized by attention deficits, hyperactivity, and impulsivity. While stimulant medications provide short-term relief for 70% of patients, their long-term effects are less understood. Researchers have been exploring non-invasive brain stimulation techniques to offer alternative solutions.
One such method is TNS, which stimulates the trigeminal nerve, aiming to activate the brainstem and subsequently influence ADHD-related regions like the locus coeruleus, responsible for arousal often lacking in ADHD patients. It's believed to stimulate attention-related brain areas in a bottom-up manner.
The Initial Promise and the Twist:
A previous small-scale trial in the US showed promising results, leading to FDA clearance. However, the control condition lacked stimulation, and blinding was not maintained, leaving room for potential placebo effects.
And this is the part most people miss: the new UK trial, conducted across Southampton and London, addressed these concerns. It involved 150 children and adolescents, aged 8-18, and employed a more rigorous placebo condition. Half received real TNS for nine hours nightly for four weeks, while the other half received a 'sham' condition with minimal stimulation, acting as a control.
Expert Insights:
Professor Katya Rubia, a renowned cognitive neuroscientist, emphasizes the importance of well-designed placebo conditions in brain therapy trials, given the significant placebo effect in high-tech treatments. She stresses the need to manage expectations and avoid false hopes.
Professor Samuele Cortese, the study lead for the Southampton site, highlights the significance of rigorous evidence in supporting informed decisions about ADHD interventions. This empowers patients and families to choose treatments wisely.
Dr. Aldo Conti, the study's first author, explains that their trial included adolescents, a crucial group due to medication adherence challenges. This broader approach ensures a more robust and clinically meaningful evaluation.
The Verdict:
While the device was deemed safe, the trial revealed no significant improvement in ADHD symptoms, hyperactivity, attention, or related behaviors. This finding prompts a re-evaluation of the device's effectiveness and highlights the importance of comprehensive research in medical device approval processes.
This study, funded by the Efficacy and Mechanism Evaluation Programme, was a collaborative effort involving multiple NHS trusts and research institutions, showcasing the dedication to advancing ADHD treatment options.
